Merdury Biopharmaceutical Corp Sustainability Reports

Merdury Biopharmaceutical Corporation operates as a specialty pharmaceutical company focused on drug formulation and development for unmet medical needs in Taiwan. The company provides the StackDose platform, an innovative drug development technology integrating formulation design, 3D powder printing, and automated manufacturing systems.

Sector: Manufacturing

Country: Taiwan

Exchange: Taipei Exchange

FIGI: BBG01BYYBXS7

4 reports from 2022 to 2025

• Merdury Biopharmaceutical Corp 2025 Consolidated Financial Report and Independent Auditors' Report
• Merdury Biopharmaceutical Corp 2024 Consolidated Financial Report and Auditor's Report
• Merdury Biopharmaceutical Corp 2023 Individual Financial Report and Independent Auditors' Report
• Merdury Biopharmaceutical Corp 2022 Financial Report and Independent Auditors' Report